Oct 2026· Journal of Hematology & Oncology· Vol 19· 0 citations· 190 references
Medicine
TL;DR
The role of intensive cytarabine plus anthracycline plus anthracycline-based regimens and venetoclax-based lower-intensity approaches are discussed, as well as targeted therapies directed against FLT3, IDH1/2, NPM1, and KMT2A-rearranged AML.
Abstract
The management of acute myeloid leukemia (AML) has undergone a remarkable transformation over the past decade, as advances in genomic profiling and drug development have expanded therapeutic options and enabled increasingly personalized treatment approaches. This review summarizes the evolving therapeutic landscape of AML, including current intensive and lower-intensity treatment backbones, approved molecularly targeted therapies, and emerging investigational strategies. We discuss the role of intensive cytarabine plus anthracycline-based regimens and venetoclax-based lower-intensity approaches, as well as targeted therapies directed against FLT3, IDH1/2, NPM1, and KMT2A-rearranged AML. We further examine efforts to optimize existing treatment paradigms through the incorporation of venetoclax into intensive chemotherapy, rational targeted combinations, and novel triplet regimens, in addition to the emerging use of highly active lower-intensity therapies in younger fit patients. Finally, we highlight promising future directions in AML, including therapies targeting RAS/MAPK signaling, emerging approaches for TP53-mutated disease, and immunotherapeutic strategies. AML treatment is rapidly evolving from broadly applied chemotherapy-based approaches toward increasingly molecularly informed and individualized therapeutic strategies. Continued advances in molecular diagnostics, targeted therapies, and synergistic combination regimens have the potential to further increase remission durability, reduce relapses, and improve long-term outcomes for patients with AML.
This review has synthesized the latest clinical evidence and international guidelines to provide an updated, evidence-based algorithm for the diagnosis and management of CLL and examined the clinical efficacy reported in pivotal trials involving patients with relapsed/refractory CLL.
The therapeutic landscape of acute myeloid leukemia (AML) has changed substantially over the past decade with the incorporation of molecularly targeted agents, lower-intensity venetoclax-based regimens, and increasingly refined genetic risk stratification. Among these advances, the combination of venetoclax with hypome...
Huan Zhang, Shi-Jie Zhang, Jing-Xin Zhang· Cancer Plus· 0 citations
Allogeneic HSCT remains a major potentially curative treatment for patients with AML at high risk of relapse. However, the rapid development of targeted agents and novel non-intensive therapies has substantially changed the therapeutic landscape, raising questions regarding the optimal timing and indications for transp...
Simona Sica, F. Frioni, M. Breccia et al.· Mediterranean Journal of Hem...· 0 citations
Acute myeloid leukemia (AML) remains a major therapeutic challenge despite remarkable advances in genomic characterization. Although molecular profiling has transformed disease classification and risk stratification, treatment for most patients continues to rely on cytotoxic chemotherapy regimens developed more than 50...
S. Meshinchi, Franco Locatelli· Haematologica· 0 citations
It is proposed that the future of DLBCL management lies not merely in the availability of novel agents, but in the rational sequencing and combination of these modalities based on dynamic molecular monitoring and individualized risk assessment—translating molecular insights into actionable clinical pathways.
B. Guo, Hai-Ke Lei, Yao Liu· World Journal of Clinical On...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.